UKMF

Future Meetings

• 19 Mar 2020 — Scientific Workshop 2020[ + ]

  The UKMF Scientific Workshop will take place on Thursday 19th March 2020 at the Cavendish Conference Centre in London.

  The theme for this meeting will be ‘Accelerating  research: better trial designs, better therapies’.

  We are delighted to welcome the Michael Morley guest speaker, Professor Mohammed Mohty from Saint Antoine Research Centre in Paris who will present a talk on ‘Redesigning the way we do clinical research for 2020’.

  The programme can be found below.

  If you wish to register please email alex@collaborativeconferences.co.uk.

  • Scientific Workshop 2020 — Matthew Jenner & Rakesh Popat
• 11 Nov 2020 — Autumn Day 2020[ + ]

  More information to follow

Past Meetings

• 07 Nov 2019 — Autumn Day 2019[ + ]

  The UKMF Autumn Day took place on Thursday 7th November 2019 at the Cavendish Conference Centre in central London.

  The theme was ‘The Management of Relapsed Disease and its Consequences’.

  Please see programme below. We had a well attended and successful meeting. We are sharing the presentations below.

  Look out for details on the Scientific Workshop programme in March 2020.

   

  • Autumn Day Programme — Dr S Stern & Dr R Soutar
  • Endpoints and treatment goals in relapsed/ refractory myeloma — Prof Xavier Leleu
  • Clinically available alternatives in the relapse setting — Dr Kevin Boyd
  • Valedictory Lecture — Prof TCM Morris
  • Where are we going with treatment costs in myeloma? — Prof Olivia Wu
  • How to manage increasing workload in the myeloma clinic — Ms Sarah Henshaw
  • Optimal management of relapsed disease — Dr Matthew Jenner
  • Myeloma Clinical Trials update — Prof Gordon Cook
  • A short term biomarker based assay predicts apoptotic response to combined BCL-2/MCL-1 BH3 mimetic targeting in myeloma cells — Dr Firas Abed
  • Loss of TRIM33 in multiple myeloma correlates with increased genomic instability — Miss Roisin McAvera
  • A ‘real-world’ study of panobinostat, bortezomib and dexamethasone in a very heavily pre-treated population of myeloma patients — Sarah Bird
  • Outcomes of newly diagnosed multiple myeloma with deferred ASCT after achieving at least VGPR following PAD induction chemotherapy in the Phase II PADIMAC study — Wei Chan
• 13 Mar 2019 — Scientific Workshop 2019[ + ]

  The UKMF Scientific Workshop took place on Wednesday 13th March 2019 at the Cavendish Conference Centre in central London.

  The theme was ‘Myeloma patient Journey – Early Diagnosis to advanced disease’.

  The Michael Morley lecture was given by Prof Sigurdur Kristensson from Iceland on ‘Early diagnosis – Learnings from iSTOPP study’. We are also delighted to welcome Dr Marc Raab from the Heidelberg University Medical Centre who will present on ‘Mechanisms of resistance in multiple myeloma’.

  • Scientific Workshop Programme — Dr Martin Kaiser & Dr Karthik Ramasamy
  • Protein dynamics in early disease — Professor Mark Drayson
  • Delay in MM diagnosis — Dr Constantinos Koshiaris
  • Multiple Myeloma treatment is associated with enhanced platelet reactivity — Dr Dalia Khan
  • MRD=minimal resistant disease? — Dr Roger Owen
  • Metabolic mechanisms of resistance — Dr Holger Auner
  • Role of immune system in development in resistant MM — Professor Gordon Cook
  • Role of imaging in early diagnosis — Dr Kevin Boyd
  • iStopMM Iceland Screens, Treats or Prevents Multiple Myeloma — Prof Sigurdur Kristinsson
  • Genetics of newly diagnosed and resistant disease — Dr Martin Kaiser
• 08 Nov 2018 — Autumn Day 2018[ + ]

  The theme for the UK Myeloma Forum Autumn Day was ‘Unusual presentations of gammopathies and associated conditions’ on Thursday 8^th November 2018 at Cavendish Conference Centre, 22 Duchess Mews, London W1G 9DT. 

  We were delighted that the Michael Morley speaker was the international myeloma star, Dr Mariví Mateos from Salamanca who gave an excellent presentation on ‘Asymptomatic myeloma: when and who to treat’.

  The full programme is available to download below. We hope to see you at our next event in March 2019 and if you wish to register, please visit www.hartleytaylor.co.uk or contact wendy@ukmf.org.uk.

   

  • Autumn Day Programme November 2018 — Neil Rabin/ Rachel Hall
  • POEMS — Dr Shirley D'Sa
  • MGRS overview and clinical cases — Dr Karthik Ramasamy
  • Solitary plasmacytomas — Dr Roger Owen
  • MGCS ('of other' clinical significance — Dr Ash Wechelakar
  • Asymptomatic myeloma: when and who to treat — Professor María-Victoria Mateos
  • Dectection of asymptomatic femoral head avascular necrosis on routine whole body MRI in patients with MM provides opportunities for joint preservation — Dr Priya Sriskandarajah
  • Introduction of European quality assessment scheme for genetic testing in Myeloma: progress and update — Polly Talley
  • Sustained MRD negativity at 12 months post-ASCT predicts outcomes for myeloma patients; a real world study — Dr Michael Austin
  • The use of the anti-emetic akynzeo for autologous stem cell transplant patients receiving high dose melphalan: results of a pilot study show reduction in emesis, nausea and length of hospital stay — Dr Rachel Hall (on behalf of Lisa Hammond)
  • Myeloma XI intensive arm/ maintenance — Prof Graham Jackson
  • MUK5 — Prof Kwee Yong
  • Myeloma XI genetics — Dr Martin Kaiser
• 14 Mar 2018 — Scientific Workshop 14 March 2018[ + ]

  The theme for the UKMF Scientific Workshop was Immunotherapy and the Myeloma Microenvironment and took place on Wednesday 14th March 2018 at the Cavendish Conference Centre, London.

  The Michael Morley lecture was brilliantly presented by Dr Niels van de Donk from the  VU University Medical Centre in Amsterdam. He presented a talk on ‘The effects of Daratumumab on plasma cells and other elements of the microenvironment’.

  A full programme can be downloaded below. Thank you once again to our generous sponsors.

  Available talks can be downloaded here.

   

  • Scientific Workshop Programme — Dr Andy Chantry
  • The importance of the tumour microenvironment in multiple myeloma — Dr Claire Edwards
  • Myeloma Rudy- current progress and next steps for patients, patient groups, clinicians and researchers — Dr Kassim Javaid
  • Investigating the bone marrow microenvironment in MGUS and multiple myeloma - evidence for early and irreversible transformation — Dr Dan Tennant
  • Mitochondria Are Transferred from Non-Malignant Stroma Cells to Malignant Plasma Cells, Via Tunnelling Nanotubes in a CD38 Dependent Mechanism, a Process That Promotes Myeloma. — Chris Marlein
  • The use of oncolytic virus therapy for myeloma shows considerable promise in pre-clinical models — Georgia Stewart
  • HUWE1 inhibition as a therapeutic strategy to target MYC in MM — Lisa Crawford
• 09 Nov 2017 — Autumn Day 2017[ + ]

  The theme for the Autumn Day meeting at SOAS on 9th November 2017 was ‘The problem with proteins and immunity’. 

  The Michael Morley lecture was presented by Dr Madhave Dhodapka, Yale University on ‘Immune environment in MGUS and multiple myeloma’.

  A full programme can be downloaded below as well as most of the talks from the day. Unfortunately, we are unable to share the presentations from Dr Dhodapka and David Thompson.

   

   

   

  • Autumn Day Programme — John Ashcroft
  • Science — Christopher Parrish
  • 18FDG-PET positivity post radiotherapy is a biomarker Dr Faye for relapse in patients with plasmacytoma — Faye Sharpley
  • Identifying ultra-high risk myeloma by integrated molecular genetic and gene expression profiling — Amy Sherborne
  • Potential toxicities and clinical issues with immunotherapies — Reuben Benjamin
  • Clinical profiles in the AL-Chemy study: a single centre prospective observational study of 1203 patients diagnosed with systemic AL amyloidosis at the UK National Amyloidosis Centre (UK NAC) — Richa Manwani
  • Immunotherapies in myeloma, where are we today? — Prof Gordon Cook & Christopher Parrish
• 03 Aug 2017 — 1st Oxford Myeloma Workshop[ + ]

  Outside of the International Myeloma workshop we lack a comprehensive educational meeting on plasma cells disorders. With significant developments in scientific understanding, diagnostic testing and guidelines, prognostication, treatment principles and treatment options there is considerable knowledge in the area of plasma cell disorders that has to be disseminated.

  As an individual interested in the field of plasma cell disorders, you would be in agreement that the last 2-3 years have seen a step change in both scientific developments, paralleled by a substantial transformation in therapeutics available in myeloma. There could not be an apposite time for us to educate and engage those working in this field.

  We are excited to put together a comprehensive workshop programme to cover all aspects of plasma cell disorders. We have a brilliant faculty both from UK as well Europe and USA, who are well respected in the field of plasma cell disorders. The course is aimed at a cross-section of haematology trainees, haematology consultants, scientists working in the field of myeloma as well as allied nursing and pharmacy colleagues.

  The First Oxford Myeloma Workshop will be held at  St Catherine’s College, Oxford, on 3rd and 4th August 2017.

  We would be delighted if you can attend this workshop. On this website we have a detailed programme, list of speakers and details of registration for the meeting. We look forward to meeting you in August, and hope that you will also have time to explore our beautiful, historic city.

   

  Dr Karthik Ramasamy          Prof Udo Oppermann           Dr Jaimal Kothari

  • 1st Oxford Myeloma Workshop — Dr Karthik Ramasamy
• 22 Mar 2017 — UKMF Spring Day 2017[ + ]

  The theme for the UKMF Spring Day will be, Personalised therapy in myeloma: Fact or Fiction? 

  • Michael Morley Lecture:  Understanding the myeloma environment by Irene Ghobrial                                                                          
  •  Patients Case histories
  • Topics: Driver mutations, MRD testing, Hevylite assays, Frailty biomarkers
  • Biomarkers for personalised therapy in Myeloma
  • ASH Bursary winners
  • Eric Low – tribute to former Myeloma UK Chief Executive

  If you would like to register for this event, please visit http://www.hartleytaylor.co.uk or contact Wendy@ukmf.org.uk

  • Spring Day Programme — UKMF
  • Making sense of prognostic factors — Dean Smith
  • Actionable/driver mutations in myeloma — Mike Chapman
  • Hevylite assays de-convoluted — Karthik Ramasamy
  • MRD testing:which platforms, which patients? — Roger Owen
  • The patient's perspective — Eric Low
  • Frailty Biomarkers — Prof Gordon Cook
• 09 Nov 2016 — UKMF Autumn Day 2016[ + ]

   

  The theme for the UKMF Autumn Day on 9th November 2016 was ‘Next Generation Therapies in Myeloma’.

  We were delighted to welcome Prof Sagar Lonial (Atlanta, USA), who presented the Michael Morley lecture on ‘Treatment of Myeloma with monoclonal antibodies’is open for registration.

   

  Talks can be downloaded below.

   

  • Autumn Day Programme 9th November 2016 — Karthik Ramasamy
  • Treatment of myeloma with monoclonal antibodies — Prof Sagar Lonial
  • New Proteasome inhibitors in myeloma — Dr Holger Auner
  • NICE guidance MM - practice implications — Dr Guy Pratt
  • What is high risk myeloma? Challenging case studies — Dr Ceri Bygrave
  • Challenging cases - double refractory MM and clinical overview of anti CD38 monoclonal antibodies — Dr Rachel Hall
  • Immunotherapy in myeloma, where do we go? — Prof Paul Moss
  • New agents in MM presenting / relapsing with renal impairmen — Karthik Ramasamy
• 20 Apr 2016 — BSH/ UKMF Symposium – April 2016, Glasgow[ + ]

  The BSH/ UKMF joint symposium at the SECC in Glasgow in April 2016 was a huge success. The theme for the symposium, was ‘Understanding Risk in Myeloma: A practical approach’.  Prof Kwee Yong and Dr Karthik Ramasamy were the session Chairs. Guest international speakers included, Phillipe Moreau (France), Sonja Sweegman (The Netherlands) and Wee Joo Chng (Singapore).

  

  

  • Risk Stratification in the older patient; what are our priorities — Dr Sonja Sweegman
  • Integrating NGS approaches into patient care: How I manage high-risk disease at presentation in a transplant eligible patient — Prof Chung Wee Joo
  • High-risk smoldering myeloma — Philippe Moreau
• 17 Mar 2016 — UKMF Spring Day 2016[ + ]

  The Spring Day had a record turn out. Talks will be available to download from this site.

  Special thanks to all our guest speakers, especially to Dr Peter Croucher, who flew from Australia to give an excellent talk on Mechanisms of bone loss in Multiple Myeloma: an increasingly important role for bone cells.

  

  • UKMF Spring Day Programme 17th March 2016 — Jenny Bird
  • Challenging Cases — Dr Neil Rabin
  • Evidence for use of CT scanning and PET-CT in managing patients with Myeloma — Dr Elena Zamagni
  • Quantitative whole-body MRI for treatment response monitoring in Multiple Myeloma — Dr Arash Latifoltojar
  • Exercise and Physiotherapy in Myeloma — Orla McCourt
  • Osteonecrosis of the jaws — Stefano Fedele
  • Bone Pain: A Practical Approach to Management — Dr Rowan Hearn